Myasthenia gravis following alemtuzumab therapy for multiple sclerosis

Alemtuzumab, indicated for active relapsing-remitting multiple sclerosis (MS), produces lymphocyte depletion followed by a different pattern of T- and B-cell repopulation, increasing the risk of secondary autoimmune diseases.1 According to the published long-term safety data, thyroid disorders are the most common autoimmune adverse event.2 Myasthenia gravis (MG), an autoimmune antibody-mediated disorder, rarely coexists in patients with MS.3,4 To date, MG has not been reported in patients with MS exposed to alemtuzumab.